Enanta Pharmaceuticals (ENTA) Return on Sales (2012 - 2026)

Enanta Pharmaceuticals' Return on Sales history runs 15 years deep, the most recent figure standing at 0.01% for Q1 2026.

• Quarterly Return on Sales rose 1.0% year-over-year to 0.01% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.01% (up 1.0% YoY) and the FY2025 annual result came in at 0.01%, changed 0.0% from the prior year.
• Return on Sales was 0.01% for Q1 2026 at Enanta Pharmaceuticals, down from 0.01% in the prior quarter.
• Across five years, Return on Sales topped out at 0.01% in Q4 2025 and bottomed at 0.02% in Q1 2023.
• A 5-year average of 0.01% and a median of 0.01% in 2023 frame the typical range for Return on Sales.
• Peak annual rise in Return on Sales reached 2 bps in 2022, while the deepest fall reached 1 bps in 2022.
• Enanta Pharmaceuticals' Return on Sales stood at 0.01% in 2022, then plunged by 51 bps to 0.02% in 2023, then grew by 29 bps to 0.01% in 2024, then soared by 51 bps to 0.01% in 2025, then decreased by 19 bps to 0.01% in 2026.
• Business Quant data shows ENTA's Return on Sales at 0.01% in Q1 2026, 0.01% in Q4 2025, and 0.01% in Q3 2025.